BMY
Lights, camera, patient awareness
Bristol Myers Squibb is putting Mariska Hargitay on the front lines of an “Investigating Myeloma” campaign, a tribute to her father and his battle with the disease 20 years ago. Think of it as part public-service announcement, part brand halo — the kind of move pharma companies love because it sounds human, not just clinical.
Why investors should care
This isn’t the sort of announcement that changes a spreadsheet by lunch. But it does matter in the softer, harder-to-measure world of brand building, especially for a company with a deep oncology footprint like BMS.
- It keeps multiple myeloma in the spotlight
- It reinforces BMS’s presence in hematology and oncology
- It gives the company a feel-good narrative that can support trust and awareness
Big picture
No, this won’t move the stock like an FDA green light or a blowout trial readout. But in pharma, reputation is part of the business model too. Sometimes the path to better medicine starts with getting people to pay attention in the first place.